Stephens Increases Alignment Healthcare (NASDAQ:ALHC) Price Target to $7.00

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) had its price objective raised by Stephens from $6.00 to $7.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an "equal weight" rating on the stock. Stephens' target price points to a potential upside of 5.58% from the company's previous close.

Other equities research analysts also recently issued reports about the stock. UBS Group lowered their target price on shares of Alignment Healthcare from $9.00 to $8.50 and set a "neutral" rating on the stock in a research note on Wednesday, February 28th. Barclays began coverage on shares of Alignment Healthcare in a research note on Wednesday, March 6th. They issued an "underweight" rating and a $4.50 target price on the stock. Piper Sandler reiterated a "neutral" rating and set a $6.00 price target (down from $12.00) on shares of Alignment Healthcare in a research report on Wednesday, March 6th. Stifel Nicolaus reduced their price target on shares of Alignment Healthcare from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Tuesday, April 23rd. Finally, Raymond James increased their price target on shares of Alignment Healthcare from $10.00 to $12.00 and gave the company a "strong-buy" rating in a research report on Tuesday, January 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Alignment Healthcare currently has a consensus rating of "Hold" and a consensus target price of $8.83.

Alignment Healthcare Price Performance

Shares of Alignment Healthcare stock traded up $1.37 on Friday, reaching $6.63. The stock had a trading volume of 3,023,068 shares, compared to its average volume of 898,686. Alignment Healthcare has a 1 year low of $4.46 and a 1 year high of $9.20. The company has a market cap of $1.26 billion, a P/E ratio of -8.39 and a beta of 1.23. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 1.02. The business's 50 day moving average is $5.11 and its two-hundred day moving average is $6.55.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). The firm had revenue of $628.60 million during the quarter, compared to analysts' expectations of $599.75 million. Alignment Healthcare had a negative return on equity of 75.64% and a negative net margin of 8.12%. The company's quarterly revenue was up 43.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.20) earnings per share. As a group, research analysts anticipate that Alignment Healthcare will post -0.6 EPS for the current year.

Insiders Place Their Bets

In other news, insider Dawn Christine Maroney sold 15,861 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $5.05, for a total transaction of $80,098.05. Following the completion of the transaction, the insider now directly owns 1,999,500 shares in the company, valued at approximately $10,097,475. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Dawn Christine Maroney sold 15,861 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $5.05, for a total transaction of $80,098.05. Following the completion of the transaction, the insider now directly owns 1,999,500 shares in the company, valued at approximately $10,097,475. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John E. Kao bought 103,000 shares of the stock in a transaction dated Thursday, March 14th. The shares were purchased at an average price of $4.82 per share, with a total value of $496,460.00. Following the completion of the transaction, the chief executive officer now directly owns 2,745,253 shares in the company, valued at approximately $13,232,119.46. The disclosure for this purchase can be found here. Insiders sold 90,213 shares of company stock worth $460,587 in the last three months. 6.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. bought a new stake in Alignment Healthcare in the first quarter worth $57,000. Barlow Wealth Partners Inc. purchased a new stake in Alignment Healthcare in the fourth quarter worth $100,000. Victory Capital Management Inc. increased its stake in Alignment Healthcare by 17.9% in the fourth quarter. Victory Capital Management Inc. now owns 12,935 shares of the company's stock worth $111,000 after purchasing an additional 1,962 shares during the period. Teza Capital Management LLC purchased a new stake in Alignment Healthcare in the third quarter worth $109,000. Finally, Aigen Investment Management LP purchased a new stake in Alignment Healthcare in the third quarter worth $116,000. 86.19% of the stock is currently owned by institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.